Scott LJ, Dalbavancin. A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs. 2015;75(11):1281–91.

Article  CAS  PubMed  Google Scholar 

Candiani G, Abbondi M, Borgonovi M, Romanò G, Parenti F. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 1999;44(2):179–92.

Article  CAS  PubMed  Google Scholar 

Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(suppl2):ii15–20.

Article  CAS  PubMed  Google Scholar 

Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy Volunteers. Antimicrob Agents Chemother. 2004;48(3):940–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carrothers TJ, Chittenden JT, Critchley I. Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. Clin Pharmacol Drug Dev. 2020;9(1):21–31.

Article  CAS  PubMed  Google Scholar 

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N Engl J Med. 2014;370(23):2169–79.

Article  PubMed  Google Scholar 

Rebold N, Alosaimy S, Pearson JC, Dionne B, Taqi A, Lagnf A, et al. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infect Dis Ther. 2024;13(3):565–79.

Article  PubMed  PubMed Central  Google Scholar 

Ajaka L, Heil E, Schmalzle S. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care. Antibiot Basel Switz. 2020;9(10):700.

CAS  Google Scholar 

Salinas-Botrán A, Olmos-Blanco C, Fernández de Velasco-Pérez D, Guzmán-Carreras A, Morales-Rosas A, Gómez-Ramírez D. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years. Enfermedades Infecc Microbiol Clin Engl Ed. 2025;43(2):71–9.

Article  Google Scholar 

Frazier JD, Stoudenmire LL, Wagner JL, Thomas GM, Steele GM, Henao-Martínez AF, et al. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents. 2023;62(1):106842.

Article  CAS  PubMed  Google Scholar 

Molina KC, Lunowa C, Lebin M, Segerstrom Nunez A, Azimi SF, Krsak M, et al. Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections. Open Forum Infect Dis. 2022;9(7):ofac335.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials. Infect Dis Ther. 2022;11(1):423–34.

Article  PubMed  Google Scholar 

Leanza GM, Rando E, Frondizi F, Taddei E, Giovannenze F, Horcajada JP, et al. A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis. Infection. 2025;53(1):15–23.

Article  CAS  PubMed  Google Scholar 

Aparicio-Minguijón E, Boán J, Terrón A, Heredia C, Puente C, Pérez-Jacoiste Asín A, et al. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients. Enfermedades Infecc Microbiol Clin Engl Ed. 2025;43(2):86–92.

Article  Google Scholar 

Suárez M, Pérez-Landeiro A, Sanjurjo A, Lima O, Sousa A, López A, et al. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2024;138:41–5.

Google Scholar 

Hidalgo-Tenorio C, Sadyrbaeva-Dolgova S, Enríquez-Gómez A, Muñoz P, Plata-Ciezar A, Miró JM, et al. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci. Int J Antimicrob Agents. 2023;62(3):106918.

Article  CAS  PubMed  Google Scholar 

Durante-Mangoni E, Boccia F, Ursi MP, Karruli A, Andini R, Galdo M, et al. Dalbavancin for infective endocarditis: a single centre experience. J Chemother Florence Italy. 2021;33(4):256–62.

Article  CAS  Google Scholar 

Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(5):795–8.

Article  CAS  Google Scholar 

Lovatti S, Tiecco G, Mulé A, Rossi L, Sforza A, Salvi M, et al. Dalbavancin in Bone and Joint Infections: A Systematic Review. Pharm Basel Switz. 2023;16(7):1005.

CAS  Google Scholar 

Dimopoulou D, Mantadakis E, Koutserimpas C, Samonis G. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. Antibiot Basel Switz. 2023;12(10):1492.

CAS  Google Scholar 

Cain AR, Bremmer DN, Carr DR, Buchanan C, Jacobs M, Walsh TL, et al. Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis. Open Forum Infect Dis. 2022;9(2):ofab589.

Article  PubMed  Google Scholar 

Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open Forum Infect Dis. 2019;6(1):ofy331.

Article  PubMed  Google Scholar 

Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville É, et al. Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study. J Antimicrob Chemother. 2023;78(12):2919–25.

Article  CAS  PubMed  Google Scholar 

Dimitrova M, Gilchrist M, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open. 2021;11(9):e049733.

Article  PubMed  PubMed Central  Google Scholar 

Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, et al. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. Trials. 2022;23(1):407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freling S, Wald-Dickler N, Banerjee J, Canamar CP, Tangpraphaphorn S, Bruce D, et al. Real-World Application of Oral Therapy for Infective Endocarditis: A Multicenter, Retrospective, Cohort Study. Clin Infect Dis. 2023;77(5):672–9.

Article  CAS  PubMed  Google Scholar 

Parruti G, Polilli E, Coladonato S, Rapacchiale G, Trave F, Mazzotta E, et al. Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections. Antibiot Basel Switz. 2024;13(11):1063.

CAS  Google Scholar 

Esposito S, Pagliano P, De Simone G, Guarino A, Pan A, Brambilla P, et al. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry. Infection. 2024;52(4):1297–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zambrano S, Paras ML, Suzuki J, Pearson JC, Dionne B, Schrager H, et al. Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs. Open Forum Infect Dis. 2024;11(4):ofae186.

Article  PubMed  PubMed Central  Google Scholar 

McSorley JC, Reyes D, Tonna I, Bateman V. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service. Infection. 2024;52(2):567–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital. Microbiol Spectr. 2023;11(1):e0238522.

Article  PubMed  Google Scholar 

Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74(8):2405–16.

Article  CAS  PubMed  Google Scholar